Safety and efficacy of durvalumab (MEDI4736) in various solid tumors

INTRODUCTION: The prominent immune checkpoint molecule, programmed cell death ligand-1 (PD-L1), is the object of increasing attention. Here, we report a meta-analysis investigating the safety and efficacy of durvalumab (MEDI4736), an inhibitor of PD-L1, in various solid tumors. METHODS: A systematic...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Hui, Shen, Kai, Zhu, Chenjing, Li, Qingfang, Zhao, Yunuo, Ma, Xuelei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6038862/
https://www.ncbi.nlm.nih.gov/pubmed/30013326
http://dx.doi.org/10.2147/DDDT.S162214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6038862/
https://www.ncbi.nlm.nih.gov/pubmed/30013326
http://dx.doi.org/10.2147/DDDT.S162214

Ejemplares similares